When your doctor mentions “ketamine treatment” for depression, you might feel confused about what that actually means. Are they talking about the same ketamine that’s sometimes misused recreationally? What’s the difference between the treatments you’ve been hearing about? You’re not alone in this confusion.
Two main forms of medical ketamine are available for treating severe depression: IV ketamine infusions and intranasal esketamine (brand name Spravato). While both use the same core medicine, they work differently in your body and involve completely different treatment experiences. Harvard’s largest-ever comparison study in 2025 has finally provided clear answers about how these treatments compare in real-world settings.
Key takeaway:
Harvard’s 2025 study of 153 patients found IV ketamine produces faster symptom relief after the first treatment compared to esketamine’s typical second-treatment response, with 49% versus 40% depression score reductions. However, both treatments are highly effective for treatment-resistant depression, and the choice often comes down to practical factors like cost, insurance coverage, and treatment setting preferences.
Understanding the Two Ketamine Treatments
IV ketamine uses racemic ketamine, which contains both forms of the ketamine molecule (R and S versions), delivered directly into your bloodstream through an IV line. This treatment happens in specialized clinics or hospital settings over 40-60 minutes, usually twice weekly for several weeks. The medication is generic and has been used off-label for depression treatment since research showed its rapid antidepressant effects.
Intranasal esketamine (Spravato) uses only the S-form of ketamine, which has stronger activity at brain receptors involved in depression. You spray this medication into your nose at certified treatment centers, where you must be monitored for two hours afterward due to FDA safety requirements. Esketamine received official FDA approval specifically for treatment-resistant depression in 2019.
The regulatory difference matters more than you might think. IV ketamine operates in a gray area where doctors prescribe it “off-label,” meaning insurance coverage varies widely and many patients pay out-of-pocket. Esketamine, being FDA-approved, typically has clearer insurance pathways, though prior authorization requirements can be extensive.
Both treatments cause temporary side effects during administration, including dissociation (feeling disconnected from yourself or surroundings), dizziness, and blood pressure changes. These effects are carefully monitored and typically resolve within a few hours.
Harvard’s Groundbreaking 2025 Study Results
The McLean Hospital and Mass General Brigham research team conducted the first large-scale, real-world comparison of IV ketamine versus esketamine treatments. Their study followed 153 adults with severe treatment-resistant depression who had failed multiple previous antidepressant attempts.
Unlike controlled clinical trials that exclude many real patients, this study included people with active suicidal thoughts and complex medical histories. Researchers tracked patients through their actual treatment experiences at established ketamine clinics, measuring depression scores before and after treatment courses.
The results showed meaningful differences in both speed and magnitude of response. Patients receiving IV ketamine typically experienced significant improvement after their first infusion, while esketamine patients usually needed at least two sessions before seeing substantial changes. By the end of treatment courses, IV ketamine patients showed an average 49% reduction in depression scores compared to 40% for esketamine patients.
However, the researchers emphasized important limitations. This wasn’t a randomized controlled trial, meaning doctors and patients chose which treatment to use based on individual factors. Selection bias could influence results, and the study couldn’t determine whether IV ketamine is definitively “superior” to esketamine for all patients.
What the study does “settle” is that both treatments work well for people with severe, treatment-resistant depression. The debate isn’t about which treatment is effective, but rather which practical trade-offs matter most for individual patients.
Real-World Effectiveness Data
Beyond Harvard’s comparison study, separate research provides encouraging data about ketamine treatments for the most challenging cases. The University of Michigan’s Bio-K study specifically enrolled patients with active suicidal ideation, a group typically excluded from antidepressant research due to safety concerns.
In this high-risk population, 52% achieved clinical remission after just three IV ketamine sessions. This represents a remarkable success rate considering these patients had failed multiple previous treatments and were experiencing thoughts of suicide when they started ketamine therapy.
Treatment-resistant depression, defined as failing to respond to at least two different antidepressant medications, affects roughly one-third of people with major depression. Traditional antidepressants can take 6-8 weeks to show full effects, if they work at all. Ketamine treatments typically show responses within hours to days, offering hope for people who’ve waited months or years for relief.
The speed difference matters enormously when someone is struggling with suicidal thoughts or severe depression that prevents basic functioning. Early response after the first or second ketamine treatment can provide the motivation and mental clarity needed to engage with therapy and other recovery activities.
Both IV ketamine and esketamine have shown sustained benefits in follow-up studies, though maintenance treatments are typically needed to prevent relapse. The frequency of maintenance varies widely between individuals, from monthly to every few months.
Practical Treatment Differences
| Factor | IV Ketamine | Esketamine (Spravato) |
|---|---|---|
| Administration | IV infusion over 40-60 minutes | Nasal spray self-administered |
| Treatment Setting | Private ketamine clinics or hospitals | Certified medical facilities only |
| Monitoring Time | During infusion plus 30-60 minutes | 2 hours mandatory observation |
| FDA Status | Off-label use of generic medication | FDA-approved specifically for depression |
| Insurance Coverage | Variable, often limited | Better coverage but requires prior authorization |
| Out-of-Pocket Cost | $300-800 per session | $300-900 per session (if not covered) |
| Frequency | Usually twice weekly initially | Twice weekly for 4 weeks, then weekly or less |
| Concurrent Requirements | Can be used alone or with other treatments | Must be combined with oral antidepressant |
The cost differences aren’t straightforward. While IV ketamine uses an inexpensive generic drug, the clinic administration and monitoring add significant expenses. Esketamine is much more expensive as a medication, but insurance coverage can make it more affordable for patients who qualify.
Insurance coverage for esketamine requires documenting treatment resistance, typically meaning you’ve tried and failed at least two different antidepressants for adequate durations. Some insurers also require prior therapy attempts and ongoing psychiatric care.
Treatment scheduling differs significantly between options. IV ketamine clinics often offer more flexible scheduling, including evening or weekend appointments. Esketamine treatment must occur at certified facilities during regular medical hours, with the two-hour monitoring requirement affecting work and family schedules.
Geographic availability varies by region. Major cities typically have multiple IV ketamine clinics, while esketamine-certified facilities may be more limited. Rural areas might have better access to esketamine through hospital systems than to specialized ketamine clinics.
What to Expect During Treatment
IV ketamine treatment begins with establishing an IV line, similar to receiving fluids at a hospital. You’ll sit in a comfortable chair while the medication infuses over 40-60 minutes. Many clinics provide eye masks, blankets, and calming music to enhance the experience. Some patients describe floating sensations, visual changes, or feeling disconnected from their body.
The dissociative effects typically peak about 20 minutes into the infusion and gradually fade. Most people remain conscious and can communicate with staff if needed, though many prefer to rest quietly. After the infusion ends, you’ll be monitored for 30-60 minutes until effects subside enough for safe transportation home.
Esketamine treatment involves self-administering nasal spray doses under medical supervision. You’ll spray the medication into each nostril, rotate the device, and repeat the process. The onset of effects is usually faster than IV treatment, within 15-20 minutes. The dissociation and other side effects follow similar patterns but may feel more intense due to the quicker onset.
The mandatory two-hour observation period allows medical staff to monitor blood pressure, heart rate, and mental status. You can’t drive or operate machinery for the rest of the treatment day, so arrange transportation in advance.
Both treatments can cause nausea, particularly in the first few sessions. Eating lightly beforehand and staying hydrated helps minimize this side effect. Some treatment centers offer anti-nausea medication if needed.
Many patients report improved mood or clarity within hours of their first treatment, though effects may fluctuate initially. The antidepressant benefits typically build and stabilize over multiple sessions. It’s important to continue other treatments like therapy and prescribed medications unless your doctor recommends changes.
Making the Right Choice for Your Situation
The decision between IV ketamine and esketamine often comes down to practical considerations rather than medical effectiveness alone. Both treatments show similar success rates for treatment-resistant depression, so your individual circumstances should guide the choice.
Consider IV ketamine if: you need flexible scheduling, have limited insurance coverage for esketamine, prefer shorter monitoring periods, or live near established ketamine clinics. The faster initial response might also be important if you’re in crisis and need rapid symptom relief.
Consider esketamine if: you have insurance coverage that includes mental health benefits, prefer FDA-approved treatments with extensive safety data, or need treatment coordination through your existing psychiatric provider. The structured monitoring and required concurrent antidepressant therapy provide additional safety oversight.
Financial considerations require careful evaluation. Even with insurance coverage, esketamine often involves significant copays or deductibles. IV ketamine’s cash-pay model provides predictable costs but requires upfront payment. Many ketamine clinics offer financing options or treatment packages that reduce per-session costs.
Treatment intensity differs between approaches. IV ketamine protocols are often more flexible, allowing adjustments based on your response. Esketamine follows more rigid FDA-approved protocols, which provides consistency but less individualization.
Your current psychiatric care team’s familiarity with each treatment matters. Some psychiatrists have extensive experience with one approach but not the other. Continuing with your existing provider might influence which treatment is most practical.
Geographic and scheduling factors significantly impact treatment feasibility. Consider travel time, parking availability, and your ability to arrange transportation after sessions. Missing treatments due to logistical challenges can compromise outcomes.
Frequently Asked Questions
Which treatment is more effective for severe depression?
Harvard’s 2025 study suggests IV ketamine produces slightly faster and stronger responses (49% versus 40% symptom reduction), but both treatments are highly effective for treatment-resistant depression. The “best” choice depends more on your individual situation, insurance coverage, and treatment preferences than on small differences in effectiveness.
How long do the benefits last after treatment?
Initial benefits can last days to weeks after single treatments, but sustained improvement typically requires ongoing maintenance sessions. Most people need maintenance treatments every 2-8 weeks to prevent relapse, with frequency varying based on individual response and other treatments you’re receiving.
Should I be concerned about addiction or dependence?
At therapeutic doses used in medical settings, the risk of developing ketamine dependence is considered low. However, ketamine does have abuse potential, and people with histories of substance use disorders should discuss this concern with their treatment team. IV ketamine may be used cautiously in some dual diagnosis patients, though providers evaluate on a case-by-case basis due to potential substance use relapse risks.
Will insurance cover these treatments?
Esketamine (Spravato) has better insurance coverage due to FDA approval, but requires prior authorization showing you’ve failed other treatments first. IV ketamine coverage varies widely by insurer and is often limited, meaning many patients pay out-of-pocket. Contact your insurance company to understand your specific coverage before starting treatment.
What if I have a history of addiction in recovery?
This is an important consideration that shouldn’t prevent you from accessing effective depression treatment. Many treatment centers have experience working with people in recovery and can provide additional safety measures and support. Staff with lived recovery experience, like those at many treatment centers, understand these concerns and can help you navigate treatment safely while maintaining your recovery goals.
Key Takeaways
- Harvard’s 2025 study confirms that both IV ketamine and esketamine are highly effective treatments for treatment-resistant depression, with IV ketamine showing somewhat faster and stronger responses in real-world settings.
- The choice between treatments should be based on practical factors like insurance coverage, scheduling flexibility, and treatment setting preferences rather than effectiveness alone.
- Both options offer hope for people who haven’t responded to traditional antidepressants, with many patients experiencing rapid symptom relief within hours or days of treatment.
- The integration of ketamine therapy with comprehensive mental health care, including trauma-informed therapy and ongoing psychiatric support, maximizes the chances of sustained recovery.
- The “debate” isn’t really settled in terms of declaring one treatment superior, but rather in confirming that both pathways can lead to significant depression relief.
Ready to explore treatment options for severe depression? Our trauma-informed care team understands the complexities of treatment-resistant depression and can help you navigate all available options, including referrals to ketamine treatment providers when appropriate.
Contact us at (866) 425-1912 to discuss your treatment options.
